Valneva SE - ADR opened lower at $5.91, compared with its previous close of $5.92. In the last trading session, the stock traded between $5.73 and $5.91. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Valneva SE - ADR is now worth
$ 11.60
Resulting in a loss of
$ 88.40 (88.40%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.13 (-2.21%)
Day High
$5.91
Day Low
$5.73
Day Open
$5.91
Prev Close
$5.92
Volume
5,145
1W Return
0.68%
1M Return
-2.05%
3M Return
3.38%
6M Return
-8.11%
1Y Return
-34.88%
Market Cap ($ Mn)
551
PE Ratio
-
PB Ratio
15.56
PEG Ratio
-
ROE
-79.70%
ROCE
-21.62%
EPS (TTM)
$-0.16
1 Week
0.68%
1 Month
-2.05%
3 Months
3.38%
6 Months
-8.11%
9 Months
-40.26%
Valneva reports 94% seroresponse for IXCHIQ vaccine at five-year mark
Valneva reports **94%** seroresponse rate for IXCHIQ vaccine five years post-vaccination. Study involved **221** evaluable adults with similar immune persistence in ages 18-64 and 65+. Real-world data includes **80,000** doses administered in Brazil between February and October 2026. FDA suspended US license in August 2025 due to serious adverse events; Valneva withdrew BLA in January.
2 days agoValneva S4V2 vaccine meets primary endpoint in phase 2 trial
S4V2 met primary endpoint in adult CHIM trial with significant reduction in shigellosis incidence. Infant trial showed favorable safety and significant antibody increases across all four serotypes. Shares rose 5.26% to $5.80 following the positive Phase 2 data announcement.
3 days agoValneva SE to report 9M 2026 results on November 24
Valneva SE will report nine-month 2026 financial results on November 24, 2026. Live webcast scheduled for 3 p.m. CET (9 a.m. ET) with business update. Company markets three proprietary travel vaccines and has a Lyme disease vaccine under review.
8 days agoValneva SE to present at US and Europe healthcare conferences in Nov
Valneva SE management will present at four healthcare conferences in the US and Europe between October and November 2026. Primary discussion topics include the regulatory outlook for the Lyme disease vaccine candidate partnered with Pfizer. Regulatory decisions for the Lyme vaccine are expected within the next 12 months. Events include Portzamparc, Guggenheim, Stifel, and Jefferies conferences across Paris, Boston, New York, and London.
29 days agoValneva Q2FY26 Results: Product sales drop 30% YoY, cash rises to €121.5 million
Product sales declined 29.7% YoY to €64 million in H1 2026. Operating loss widened to €49.9 million from €16.8 million in prior year. Cash position increased to €121.5 million from €109.6 million at FY25 end. Full-year revenue guidance reaffirmed at €145–€160 million. Lyme vaccine regulatory decisions expected within next 12 months.
29 days agoUK regulators revoke Valneva's IXCHIQ marketing authorization
MHRA revoked UK marketing authorization for Valneva's chikungunya vaccine IXCHIQ. Decision based on prior safety data with no new safety signals identified. Minimal financial impact expected as UK distribution had already ceased. Approvals remain intact in EU, Canada, Brazil, and other global markets.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Valneva SE - ADR is now worth
$ 11.60
Resulting in a loss of
$ 88.40 (88.40%)
Note: Past profits do not guarantee future returns.
